Browsing Tag
TLX592
1 post
Telix Pharmaceuticals advances prostate cancer treatment with successful TLX592 study
Telix Pharmaceuticals Limited (ASX: TLX) has announced the successful completion of the CUPID Phase I dose escalation study…